Inhibrx Biosciences, Inc. INBX Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $113.03M-44.5% | $203.74M+6.3% | ||
| $23.3M-81.8% | $127.91M+335% | ||
| $136.33M-58.9% | $331.65M+50.1% | ||
| -$135.03M+59.3% | -$331.45M-51.2% | ||
| $12.2M-9.6% | $13.49M-57.6% | ||
| -$5.03M-100% | $2.02B+9,947% | ||
| -$140.05M-108% | $1.74B+824% | ||
| $2K0.0% | $2K— | ||
| -$140.06M-108% | $1.74B+819% | ||
| -$9.04-108% | $116.87+671% | ||
| -$132.54M+59.7% | -$329.16M-51.0% | ||
| -$135.03M+59.3% | -$331.45M-51.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Inhibrx Biosciences, Inc.'s revenue?
- Inhibrx Biosciences, Inc. (INBX) generated $1.3M in revenue over the trailing twelve months, up 550.0% year over year.
- Is Inhibrx Biosciences, Inc. profitable?
- Inhibrx Biosciences, Inc. is not currently profitable: it reported a net loss of $130.2M over the trailing twelve months, a -10773.5% net margin.
- What is Inhibrx Biosciences, Inc.'s earnings per share?
- Inhibrx Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-8.39.
- Where does Inhibrx Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
